Pharmacokinetic Comparison Between a Fixed-Dose Combination of Atorvastatin/Omega-3-Acid Ethyl Esters and the Corresponding Loose Combination in Healthy Korean Male Subjects

References

• Nikos Pappan AR. Dyslipidemia. Treasure Island (FL): StatPearls Publishing; 2022.
   Google Scholar
• Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38(32):2459–2472. doi:10.1093/eurheartj/ehx144
   PubMed Web of Science ®Google Scholar
• Cholesterol Treatment Trialists, C. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670–1681. doi:10.1016/S0140-6736(10)61350-5
   PubMed Web of Science ®Google Scholar
• Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet. 2005;366(9493):1267–1278. doi:10.1016/S0140-6736(05)67394-1
   PubMed Web of Science ®Google Scholar
• Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. J Am Coll Cardiol. 2019;73(24):e285–e350. doi:10.1016/j.jacc.2018.11.003
   PubMed Web of Science ®Google Scholar
• Jellinger PS, Handelsman Y, Rosenblit PD, et al. American Association of clinical endocrinologists and American college of endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease. Endocr Pract. 2017;23:1–87. doi:10.4158/EP171764.APPGL
   PubMed Web of Science ®Google Scholar
• Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J. 2019;41(1):111–188.
   Web of Science ®Google Scholar
• Harris WS, Miller M, Tighe AP, et al. Omega-3 fatty acids and coronary heart disease risk: clinical and mechanistic perspectives. Atherosclerosis. 2008;197(1):12–24. doi:10.1016/j.atherosclerosis.2007.11.008
   PubMed Web of Science ®Google Scholar
• Shearer GC, Savinova OV, Harris WS. Fish oil -- how does it reduce plasma triglycerides? Biochim Biophys Acta. 2012;1821(5):843–851. doi:10.1016/j.bbalip.2011.10.011
   PubMed Web of Science ®Google Scholar
• Oscarsson J, Hurt-Camejo E. Omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid and their mechanisms of action on apolipoprotein B-containing lipoproteins in humans: a review. Lipids Health Dis. 2017;16(1):149. doi:10.1186/s12944-017-0541-3
   PubMed Web of Science ®Google Scholar
• Davidson MH, Stein EA, Bays HE, et al. Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study. Clin Ther. 2007;29(7):1354–1367. doi:10.1016/j.clinthera.2007.07.018
   PubMed Web of Science ®Google Scholar
• Yokoyama M, Origasa H, Matsuzaki M, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet. 2007;369(9567):1090–1098. doi:10.1016/S0140-6736(07)60527-3
   PubMed Web of Science ®Google Scholar
• Kim JH, Sunwoo J, Song JH, et al. Pharmacokinetic interaction between atorvastatin and omega-3 fatty acid in healthy volunteers. Pharmaceuticals. 2022;15(8):962. doi:10.3390/ph15080962
   Web of Science ®Google Scholar
• Woo JS, Hong SJ, Cha DH, et al. Comparison of the efficacy and safety of atorvastatin 40 mg/ω-3 fatty acids 4 g fixed-dose combination and atorvastatin 40 mg monotherapy in hypertriglyceridemic patients who poorly respond to atorvastatin 40 mg monotherapy: an 8-week, multicenter, randomized, double-blind Phase III Study. Clin Ther. 2021;43(8):1419–1430. doi:10.1016/j.clinthera.2021.07.001
   PubMed Web of Science ®Google Scholar
• Chung I, Oh J, Lee S, et al. A post hoc analysis of intra-subject coefficients of variation in pharmacokinetic measures to calculate optimal sample sizes for bioequivalence studies. Transl Clin Pharmacol. 2018;26(1):6–9. doi:10.12793/tcp.2018.26.1.6
   PubMedGoogle Scholar
• Davidson MH, Johnson J, Rooney MW, et al. A novel omega-3 free fatty acid formulation has dramatically improved bioavailability during a low-fat diet compared with omega-3-acid ethyl esters: the ECLIPSE (Epanova(®) compared to Lovaza(®) in a pharmacokinetic single-dose evaluation) study. J Clin Lipidol. 2012;6(6):573–584. doi:10.1016/j.jacl.2012.01.002
   PubMed Web of Science ®Google Scholar
• Whitfield LR, Stern RH, Sedman AJ, et al. Effect of food on the pharmacodynamics and pharmacokinetics of atorvastatin, an inhibitor of HMG-CoA reductase. Eur J Drug Metab Pharmacokinet. 2000;25(2):97–101. doi:10.1007/BF03190074
   PubMed Web of Science ®Google Scholar
• Guidance for Industry. Bioequivalence Studies with Pharmacokinetic End-Points for Drugs Submitted Under an Anda. U.S. Food and Drug Administration; 2021.
   Google Scholar
• Lawson LD, Hughes BG. Absorption of eicosapentaenoic acid and docosahexaenoic acid from fish oil triacylglycerols or fish oil ethyl esters co-ingested with a high-fat meal. Biochem Biophys Res Commun. 1988;156(2):960–963. doi:10.1016/S0006-291X(88)80937-9
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. Draft Guidance on Omega-3-Acid Ethyl Esters. U.S. Food and Drug Administration; 2020.
   Google Scholar
• Jackson PA, Husberg C, Hustvedt S-O, et al. Diurnal rhythm of plasma EPA and DHA in healthy adults. Prostaglandins Leukot Essent Fatty Acids. 2020;154:102054. doi:10.1016/j.plefa.2020.102054
   PubMed Web of Science ®Google Scholar
• Lapointe J-F, Harvey L, Aziz S, et al. A single-dose, comparative bioavailability study of a formulation containing OM3 as phospholipid and free fatty acid to an ethyl ester formulation in the fasting and fed states. Clin Ther. 2019;41(3):426–444. doi:10.1016/j.clinthera.2019.01.017
   PubMed Web of Science ®Google Scholar
• Jing S, Zhang Z, Chen X, et al. Pharmacokinetics of single and multiple doses of omega-3 carboxylic acids in healthy Chinese subjects: a Phase I, open-label study. Clin Pharmacol Drug Dev. 2020;9(8):985–994. doi:10.1002/cpdd.800
   PubMed Web of Science ®Google Scholar
• Chevalier L, Plourde M. Comparison of pharmacokinetics of omega-3 fatty acid supplements in monoacylglycerol or ethyl ester in humans: a randomized controlled trial. Eur J Clin Nutr. 2021;75(4):680–688. doi:10.1038/s41430-020-00767-4
   PubMed Web of Science ®Google Scholar
• Chevalier L, Vachon A, Plourde M. Pharmacokinetics of supplemental omega-3 fatty acids esterified in monoglycerides, ethyl esters, or triglycerides in adults in a randomized crossover trial. J Nutr. 2021;151(5):1111–1118. doi:10.1093/jn/nxaa458
   PubMed Web of Science ®Google Scholar
• Metherel AH, Irfan M, Klingel SL, et al. Compound-specific isotope analysis reveals no retroconversion of DHA to EPA but substantial conversion of EPA to DHA following supplementation: a randomized control trial. Am J Clin Nutr. 2019;110(4):823–831. doi:10.1093/ajcn/nqz097
   PubMed Web of Science ®Google Scholar
• Metherel AH, Rezaei K, Lacombe RJS, et al. Plasma unesterified eicosapentaenoic acid is converted to docosahexaenoic acid (DHA) in the liver and supplies the brain with DHA in the presence or absence of dietary DHA. Biochim Biophys Acta Mol Cell Biol Lipids. 2021;1866(8):158942. doi:10.1016/j.bbalip.2021.158942
   PubMed Web of Science ®Google Scholar